Biotech Veteran Marc Yoskowitz Named Evozyne CEO

04 Jan 2024
www.businesswire.com
Executive Change
CHICAGO--(BUSINESS WIRE)--Chicago-based Evozyne today announced Marc Yoskowitz as CEO of the generative AI-driven biotech.
'The application of AI in healthcare has reached an inflection point to accelerate drug discovery and help patients who lack effective treatments. Leading a company that is pioneering this technology and developing novel proteins is an unparalleled opportunity'
Yoskowitz, most recently chief strategy officer and executive vice president, life sciences, at Tempus AI, will further develop the company’s strategy, focusing its generative AI platform on drug discovery in areas of high unmet patient need. Yoskowitz has held executive leadership positions with Pfizer, Hospira and McKinsey & Company, bringing deep biopharmaceutical, corporate development and strategy expertise to the role.
“The application of AI in healthcare has reached an inflection point to accelerate drug discovery and help patients who lack effective treatments. Leading a company that is pioneering this technology and developing novel proteins is an unparalleled opportunity,” Yoskowitz said. “Evozyne is focused on developing a strong pipeline of promising treatments and I look forward to leading this world-class team to address unmet patient needs.”
In its first three years, Evozyne delivered functional proof-of-concept results for strategic partners including NVIDIA and Takeda, producing proteins designed to high-performance specifications for therapeutic applications. Its investors include OrbiMed, Fidelity Management & Research Company, NVentures, NVIDIA’s venture capital arm, Paragon Biosciences and Valor Equity Partners.
Yoskowitz succeeds Mike Gamson, who refined Evozyne’s corporate strategy and closed Series B financing in 2023. Gamson was named vice chair of Evozyne’s board of directors and will maintain an advisory role.
Founded in 2020 by Paragon Biosciences, Evozyne develops novel proteins that solve high-impact problems in human health. It is developing therapeutic platforms focused on immune response modulation and high-performance gene editors.
About Evozyne
Evozyne creates novel protein systems that enable a healthier world. For more information, visit https://www.evozyne.com/.
Paragon Biosciences is a global life science leader that creates, builds and funds innovative biology-based companies. We accelerate scientific breakthroughs to address unmet medical needs. Learn more at https://www.paragonbiosci.com.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.